home page banner.png

Localized Modulation of Immune
and Inflammatory Responses for

Treatment of Diabetes and Other Conditions

Vibrin2.png
Vicapsyn2.png

Alginate Encapsulated Insulin-Producing Cells Protected from Immune System Rejection

LEARN MORE
home page banner.png
CXC platforrm logo 3 black.png

ABOUT US

We have a broad portfolio (8 patent families) of issued and pending applications covering multiple indications/applications but for Alginate Encapsulated Insulin-Producing Cells Protected from Immune System Rejection.  Our cellular applications initially targeted to treatment of Diabetes Mellitus Type 1 through pancreatic islet cell transplantation and other indications include treatment of diabetic foot ulcers and peritoneal adhesions 

ABOUT OUR PLATFORM TECHNOLOGY

Our CXCL12 platform technology was exclusively licensed from Massachusetts General Hospital in 2013.  Our platform is broadly divided into cellular and non-cellular product lines and includes feasibility and long-term maintenance of transplanted human islet cells established in non human primate models

Vicapsyn2.png

Cell Transplantation Program For Type 1 Diabetes

Funded by and developed in partnership with the JDRF

 

Diabetes Allotransplant Experiments
n Non-Human Primates  (NHP) are On-Going

 

Identifying the optimal β-stem cell partner for clinical studies

DIABETES MARKET SCOPE

The global treatment market for type 1 diabetes will expand from $6.6b in 2013 to an estimated $13.6b by 2023.

 

From 2000-2015 diabetes costs in the U.S. nearly doubled, from $12.05 to $23.35 million.

 

The number of adults living with diabetes has almost quadrupled since 1980. 

​\

Diabetes is one of the leading causes of death in the world, and in 2012, was the direct cause of 1.5 million deaths.

LEARN MORE
Vibrin2.png
LEARN MORE

Non-Cellular Program Addresses Two Conditions

TREATMENT OF DIABETIC FOOT ULCERS

DFUs are a significant financial burden to health care systems and significantly
impact the Quality of Life indices for patients and their families

PREVENTION OF POST-PERITONEAL SURGERY ADHESIONS

An unmet medical need with more than 10 million  patients at risk
in the US and 25 million patients globally

DFU MARKET SCOPE
 

Between 1.0 - 3.5 million diabetic patients  in the United States have a history of foot ulceration

 

ADHESIONS MARKET SCOPE
 

Demand for adhesion barriers surgeries poised to grow at a CAGR of 9.2% between 2016 and 2024. 
 

 

The estimated global market of greater than US$ $USD2.7 Billion by 2020
 

 

North America market  is expected to be US$ 1.6 Billion during 2016 to 2026

LEARN MORE